Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Non-Current Assets (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Non-Current Assets for 2 consecutive years, with $22.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 51.49% to $22.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $94.5 million, a N/A change, with the full-year FY2024 number at $24.7 million, changed N/A from a year prior.
  • Non-Current Assets was $22.5 million for Q3 2025 at Pyxis Oncology, down from $23.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $47.8 million in Q1 2024 to a low of $22.5 million in Q3 2025.